Key facts
- VEROVACCiNES’s last known valuation is $12.5M (Feb 2025).
- It has raised $1.7M; the latest was Later Stage VC ($1.7M) in Mar 2025.
- Notable investors include High-Tech Gründerfonds, Bundesministerium für Bildung und Forschung, Business Angels Club Berlin-Brandenburg, Startup Elevator.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for VEROVACCiNES
- ·The full record, as it builds
Funding rounds
No funding rounds for VEROVACCiNES are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VEROVACCiNES
Developer of innovative animal vaccines designed to generate, develop, and manufacture on a patent protected recombinant platform, the Unified Vaccine Platform (UVP). The company's proprietary vaccine platform enables optimized recombinant vaccines to be developed very quickly and cost-effectively, and used in combination products, it uses recombinant strains in milk yeast Kluyveromyces lactis against pathogens in pigs, cattle, and poultry, as well as eukaryotic cells for protein modifications, enabling the healthcare sector to cure animals against immunogenic virus-like particles.
- Sector
- Healthcare
- HQ
- Halle, Germany
- Founded
- 2017
- Employees
- 12
- Website
- verovaccines.com/
- Ownership
- Privately Held (backing)
VEROVACCiNES doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VEROVACCiNES shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VEROVACCiNES in its N-PORT filings yet. We sweep new filings monthly.